Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04531033
Other study ID # LF-1
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date August 25, 2020
Est. completion date November 14, 2022

Study information

Verified date May 2024
Source University of Mary Hardin-Baylor
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to determine if twice or three times daily supplementation of Lactobacillus acidophilus MPH734 (Lacto-FreedomTM, or LF), for one week, affects acute (immediate), subacute (7 days), and post-treatment discontinuation (30-, 60-, and 90- day) lactose metabolism, gastrointestinal symptoms, and clinical markers of inflammation and safety compared to a placebo.


Description:

Participants will be included and/or excluded in the study based on the criteria below: Inclusion Criteria - Participants will be male or female between the ages of 18-55 years; - Participants will be apparently healthy and free from disease, as determined by a health history questionnaire; - Participants will not be excluded if he or she has been clinically diagnosed with a carbohydrate malabsorption disorder, or is or has been prescribed to take prescription or over-the-counter medication for such; - Participant has self-diagnosed or otherwise avoids consuming dairy, lactose, and other dairy-containing products, or regularly consumes Lactase enzymes for digestive support; - Participant agrees and can comply with the study protocol; - Participant provides signed and dated informed consent to participate in the study. Subject Exclusion Criteria - Participant is or may be pregnant, is trying to become pregnant, or is breastfeeding; - Participant is insulin-dependent or -independent diabetic. - Participant currently uses, or has discontinued the use of nicotine-containing products within twelve (12) months of the start of the study; - Participant lives or works within an environment that chronically exposes the subject to second-hand smoke; - Participant currently uses, or has discontinued the use of recreational drugs or medicinal marijuana within twelve (12) months of the start of the study; - Participant has been clinically diagnosed with a digestive disorder such as gastrointestinal disease, chronic diarrhea or constipation, irritable or inflammatory bowel syndrome, Crohn's disease, or is, or has been prescribed to take prescription or over-the-counter medication for such; - Participant has ever undergone gastric bypass surgery, or has undergone an abdominal or other gastrointestinal surgery within twelve (12) months of the start of the study; - Participant is taking, or has taken antibiotic medications within two (2) weeks of the start of the study; - Participant has undergone a colonoscopy within two (2) weeks of the start of the study, or is scheduled to receive a colonoscopy during the study; - Participant has undergone a barium study or received an enema within two (2) weeks of the start of the study, or is scheduled to, or receives such during the study; - Participant is taking, or has taken probiotics within two (2) weeks of the start of the study; - Participant uses lactose digesting enzymes during the study; - Participant is taking, or has taken weight loss, prebiotic [e.g., fructo- or galacto-oligosaccharides (FOS or GOS), psyllium, or insulin fiber, etc.], or laxative / stool softener dietary supplements, over-the-counter, or prescription medications within two (2) weeks of the start of the study; - Participant is allergic to any ingredient present within the dietary supplement or placebo treatment; - Participant reports any unusual adverse events associated with this study that, in consultation with the study investigators or the participant's doctor recommends removal from the body; - Participant fails to comply with the study protocol. Intervention Below is an overview of the study, including the phases, timepoints, and dependent variables that will be assessed. The total study duration for each subject is approximately fifteen (15) weeks - one (1) week of pre-test familiarization plus fourteen (14) weeks of intervention and testing. Subject testing will commence on a rolling enrollment basis (i.e., all subjects will not start, be tested on, and end the study at the same time). 24 hrs - 12 hrs: Restricted Diet Discontinue eating: - All grains (including pasta, bread, cereals) - Fruits - Vegetables (including any food products that contain corn, corn starch, etc) - Nuts and seeds - Beans/ Legumes - All dairy products (including cheese, ice cream, butter, and yogurt) - All meats [except those approved (below)] Allowed foods: - Baked or broiled chicken, fish or turkey (salt and pepper seasoning only) - Plain, steamed white rice - Eggs - Clear chicken or beef broth - White bread (only) - Participants may drink water, coffee, or tea; no sugar or artificial sweetener; no creamer/cream 12 hrs - 0 hrs: Fasting - Water only - No sleeping or vigorous exercise for at least (1) hour prior to any time during the breath test TIMELINE: Day -7 - 0 - Pre-screening & Familiarization - Subjects complete one-week nutrition log via MyFitnessPal Day 0 - Baseline & Acute Response (Lab Test #1; LT1) - Subject arrives 12-hr fasted (water only) and having followed the 24hr pre-test and lifestyle protocol -> Body Mass (BM) and Hydration (urine) measurements -> 5-minute seated -> Heartrate (HR) and Blood Pressure (BP) measurements -> Gastrointestinal Symptom Score -> Venous Blood collection -> Non-Alcohol Mouth Rinse -> Breath Analysis -> Treatment Dose Consumed with 8-10 fl. oz. H2O -> 30- minute seated -> 25-gram Lactose Challenge/Ingestion -> 60- minute seated -> Non-Alcohol Mouth Rinse -> Breath Analysis -> 60-minute seated -> Non-Alcohol Mouth Rinse -> Breath Analysis -> 60 minute seated -> Gastrointestinal Symptoms Score -> Non-Alcohol Mouth Rinse -> Breath Analysis Day 1 - Day 7 - Treatment Phase - Subjects consume three (3) servings per day of treatment at scheduled times and conditions for three (3) days -> On Day 4 subjects perform a Lactose Challenge / Ingestion Test at home after a12-hr fast (water only); Gastrointestinal Symptoms Score is collected prior to, and at 180 minutes postprandial (after lactose ingestion) -> Subjects continue to consume three (3) servings per day of treatment at scheduled times and conditions for three (3) days - Subjects complete one-week nutrition log Day 7 - Subacute Response (Lab Test #2; LT2) - Repeat LT1 - Subjects discontinue treatment Day 8 - Day 37 - 30- Day Post Treatment Phase - Subjects perform weekly Lactose Challenge/Ingestion Testing at home with Gastrointestinal Symptoms Scoring - Subjects complete one-week nutrition logs Day 37 - 30-Day Post Treatment Response (Lab Test #3; LT3) - Repeat LT1/LT2 testing (less the Treatment Dose + 30-minute seating pre-Lactose Challenge / Ingestion) Day 38 - Day 67 - 60-Day Post Treatment Phase - Subjects perform weekly Lactose Challenge/Ingestion Testing at home with Gastrointestinal Symptoms scoring - Subjects complete one-week nutrition logs Day 67 - 60- Day Post Treatment Response (Lab Test #4; LT4) - Repeat LT1/LT2/LT3 testing (less treatment Dose + 30-minute seated pre- Lactose Challenge/Ingestion) Day 68 - Day 97 - 90-Day Treatment Phase - Subjects perform weekly Lactose Challenge/Ingestion Testing at home with Gastrointestinal Symptoms Scoring - Subjects complete one-week nutrition logs Day 97 - 90-Day Post Treatment Response (Lab Test #5; LT5) - Repeat LT1/LT2/LT3/LT4/ testing (less Treatment Dose + 30- minute seating pre- Lactose Challenge/ Ingestion)


Recruitment information / eligibility

Status Completed
Enrollment 50
Est. completion date November 14, 2022
Est. primary completion date August 25, 2021
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 55 Years
Eligibility Inclusion Criteria: - Participants will be male or female between the ages of 18-55 years; - Participants will be apparently healthy and free from disease, as determined by a health history questionnaire; - Participants will not be excluded if he or she has been clinically diagnosed with a carbohydrate malabsorption disorder, or is or has been prescribed to take prescription or over-the-counter medication for such; - Participant has self-diagnosed or otherwise avoids consuming dairy, lactose, and other dairy-containing products, or regularly consumes Lactase enzymes for digestive support; - Participant agrees and can comply with the study protocol; - Participant provides signed and dated informed consent to participate in the study. Exclusion Criteria: - Participant is or may be pregnant, is trying to become pregnant, or is breastfeeding; - Participant currently uses, or has discontinued the use of nicotine-containing products within twelve (12) months of the start of the study; - Participant lives or works within an environment that chronically exposes the subject to second-hand smoke; - Participant currently uses, or has discontinued the use of recreational drugs or medicinal marijuana within twelve (12) months of the start of the study; - Participant has been clinically diagnosed with a digestive disorder such as gastrointestinal disease, chronic diarrhea or constipation, irritable or inflammatory bowel syndrome, Crohn's disease, or is, or has been prescribed to take prescription or over-the-counter medication for such; - Participant has ever undergone gastric bypass surgery, or has undergone an abdominal or other gastrointestinal surgery within twelve (12) months of the start of the study; - Participant is taking, or has taken antibiotic medications within two (2) weeks of the start of the study; - Participant has undergone a colonoscopy within two (2) weeks of the start of the study, or is scheduled to receive a colonoscopy during the study; - Participant has undergone a barium study or received an enema within two (2) weeks of the start of the study, or is scheduled to, or receives such during the study; - Participant is taking, or has taken probiotics within two (2) weeks of the start of the study; - Participant uses lactose digesting enzymes during the study; - Participant is taking, or has taken weight loss, prebiotic [e.g., fructo- or galacto-oligosaccharides (FOS or GOS), psyllium, or insulin fiber, etc.], or laxative / stool softener dietary supplements, over-the-counter, or prescription medications within two (2) weeks of the start of the study; - Participant is allergic to any ingredient present within the dietary supplement or placebo treatment; - Participant reports any unusual adverse events associated with this study that, in consultation with the study investigators or the participant's doctor recommends removal from the study; - Participant fails to comply with the study protocol.

Study Design


Related Conditions & MeSH terms


Intervention

Dietary Supplement:
Lactobacillus acidophilus MPH734
After supplementing with oral probiotics, it has been suggested that select probiotics capable of expressing Beta-glucosidase enzyme activity may likewise be effective treatment for lactose intolerance.
Placebo
placebo made to match dietary supplement being tested.

Locations

Country Name City State
United States University of Mary Hardin-Baylor Belton Texas

Sponsors (2)

Lead Sponsor Collaborator
Lemuel W. Taylor IV Manzo Pharmaceuticals

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Lactobacillus Acidophilus MPH734's Effect on lactose digestion in individuals who identify as lactose sensitive, intolerant, or avoid dairy. Primary outcome of this study is to determine if twice or three times daily supplementation of Lactobacillus acidophilus MPH734 (Lacto-FreedomTM, or LF), for one week, affects acute (immediate), subacute (7 days), and post-treatment discontinuation (30-, 60-, and 90- day) lactose metabolism, gastrointestinal symptoms, and clinical markers of inflammation and safety compared to a placebo. 97 days
See also
  Status Clinical Trial Phase
Not yet recruiting NCT05100719 - The Role of Irritable Bowel Syndrome in Lactose Intolerance (LION) N/A
Completed NCT02518295 - β-galactosidase Producing Probiotic Strains to Improve Lactose Digestion N/A
Completed NCT00599859 - Effects of Lactose on Fecal Microflora N/A
Completed NCT02636413 - Evaluation of LacTEST for the Diagnosis of Hypolactasia in Adults and Elderly Patients Presenting With Clinical Symptoms of Lactose Intolerance Phase 4
Completed NCT02406469 - Effects Comparison of A1 and A2 Milk on Gastrointestinal Physiology, Symptoms and Cognitive Behavior Phase 4
Terminated NCT00247806 - Prevalence of Lactose Intolerance Following Stem Cell Transplantation Phase 1
Completed NCT03814668 - Effect of Probiotic Supplementation on Lactose Maldigestion Induced by Lactose Solution N/A
Completed NCT03860051 - Association Between Lactase Deficiency, and the Small Intestinal Microbiome in Adults.
Not yet recruiting NCT06107088 - Effect of a Combination of Lactase and L. Salivarius DSM 34078 in Individuals With Lactose Intolerance N/A
Completed NCT02703987 - HYBRID: Hydrogen Breath Test in Lactose Digestion N/A
Completed NCT00395954 - Amount of Lactose Causing Symptoms in Lactose Intolerant People Phase 0
Completed NCT01593800 - The Effect of Probiotics on Lactose Intolerance N/A
Completed NCT04164394 - Effect of I31 Probiotic on Lactose Intolerance N/A
Recruiting NCT05668468 - A Bifido Bacteria to Improve Lactose Digestion and Tolerance N/A
Completed NCT03563846 - Effect of a Standard Meal on the Pharmacokinetic Profile of RP-G28 in Healthy Adult Male and Female Subjects Phase 1
Recruiting NCT02085889 - Fructose and Lactose Intolerance and Malabsorption in Functional Gastrointestinal Disorders
Completed NCT03597516 - Evaluation of the Efficacy, Durability, Safety, and Tolerability of RP-G28 in Patients With Lactose Intolerance Phase 3
Not yet recruiting NCT03563859 - Evaluation of Efficacy, Durability, Safety, and Tolerability of RP-G28 in Patients With Lactose Intolerance Phase 3
Completed NCT02171403 - Comparison of the Colonic Metabolism in Patients With Lactose Intolerance and Healthy Controls N/A
Completed NCT01145586 - A Non-inferiority, Multicenter and Randomized, Multiple-Dose Study About a Treatment to Hypolactasia Phase 3